July 23, 2018 12:34pm
Key words, “in a mouse model” of Alzheimer’s disease
CUR is up +$0.23 or +19.66% to $1.40 - enjoy the ride, be prepared for the pricing spiral and SELL
Study evaluated the effect of oral treatment with NSI-189 in established 5xFAD mouse model for Alzheimer’s disease (AD). Treatment with NSI-189 restored memory retention and learning abilities in AD mice, and reduced anxiety in control and AD mice
Results are being presented in a poster titled ‘Effect of Neurogenic Compound NSI-189 on Indices of Cognition and Anxiety in a Mouse Model (5XFAD) of Alzheimer’s Disease.’
The study was carried out by Dr. Corinne Jolivalt’s laboratory at the University of California, San Diego, and involved the oral administration of NSI-189 to mice harboring gene changes that recreate symptoms of familial Alzheimer’s disease.
Animals were treated starting at 15 weeks of age, when memory defects are first beginning to appear.
Key findings include:
- Treatment with NSI-189 significantly improved learning ability as well as retention as measured by a simple task (Barnes maze), and improved performance on a test of short term memory (Novel Object Recognition)
- Treatment with NSI-189 improved motor learning of AD mice as measured by performance on a Rotarod test
- NSI-189 treatment decreased anxiety levels in both AD mice and control mice as measured by an open field test
Data from this preclinical study “suggest” that NSI-189 may be able to mitigate or reverse the cognitive impact of Alzheimer’s disease.
Since WHEN has CUR come through with … anything but, short-term HYPE?